The approval of brensocatib for use in patients with bronchiectasis could offer the first treatment directly addressing the ...

The leading Bronchiectasis Companies such as AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici ...

Long-term antibiotics use carries the risk of resistance and side effects, representing a gap in the market for a different ...

An estimated 5.17% of patients with inflammatory bowel diseases also have bronchiectasis, as shown in chest CT scans of patients with IBD.

Bronchiectasis is a chronic airway suppurative disease in which recurrent airway infections, inflammation and remodeling have ...

The drug is manufactured by the US firm Insmed and made possible after 15 years of research by scientists from the University ...

Bronchiectasis impacts up to 500,000 Americans, but there is often misdiagnosis or delayed diagnosis as the condition can present similarly to other pulmonary conditions such as COPD or asthma.

Experts at the University of Dundee have announced promising results from a clinical trial of a potential new antibody ...

Discover how HSK31858 could transform bronchiectasis treatment by reducing flare-ups - read more about the latest trial results.

Targeting airway inflammation with investigational brensocatib reduced exacerbations with bronchiectasis, the ASPEN trial showed. The dipeptidyl peptidase 1 (DPP-1) inhibitor cut the annualized ...

The article titled "Effects of the DPP-1 Inhibitor HSK31858 in Adults with Bronchiectasis in China (SAVE-BE): A Phase 2, Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial," focuses ...

The leading Non-Cystic Fibrosis Bronchiectasis Companies such as Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, ...